LRP1 functions as an atheroprotective integrator of TGFbeta and PDFG signals in the vascular wall: implications for Marfan syndrome by Boucher, Philippe et al.
LRP1 Functions as an Atheroprotective Integrator of
TGFb and PDFG Signals in the Vascular Wall: Implications
for Marfan Syndrome
Philippe Boucher1,4, Wei-Ping Li2, Rachel L. Matz1, Yoshiharu Takayama4, Johan Auwerx3, Richard G.W. Anderson2, Joachim Herz4*
1 Institut Gilbert-Laustriat, UMR 7175 LC-1, Department of Pharmacology; Centre National de la Recherche Scientifique/Institut National de la Sante´ et
de la Recherche Medicale/Universite´ Louis Pasteur, Illkirch, France, 2Department of Cell Biology, University of Texas Southwestern Medical Center,
Dallas, Texas, United States of America, 3 Institut de Ge´ne´tique et de Biologie Mole´culaire et Cellulaire, Centre National de la Recherche Scientifique/
Institut National de la Sante´ et de la Recherche Medicale/Universite´ Louis Pasteur, Illkirch, France, 4Department of Molecular Genetics, University of
Texas Southwestern Medical Center, Dallas, Texas, United States of America
Background. The multifunctional receptor LRP1 controls expression, activity and trafficking of the PDGF receptor-b in vascular
smooth muscle cells (VSMC). LRP1 is also a receptor for TGFb1 and is required for TGFbmediated inhibition of cell proliferation.
Methods and Principal Findings.We show that loss of LRP1 in VSMC (smLRP2) in vivo results in a Marfan-like syndrome with
nuclear accumulation of phosphorylated Smad2/3, disruption of elastic layers, tortuous aorta, and increased expression of the
TGFb target genes thrombospondin-1 (TSP1) and PDGFRb in the vascular wall. Treatment of smLRP12 animals with the PPARc
agonist rosiglitazone abolished nuclear pSmad accumulation, reversed the Marfan-like phenotype, and markedly reduced
smooth muscle proliferation, fibrosis and atherosclerosis independent of plasma cholesterol levels. Conclusions and
Significance. Our findings are consistent with an activation of TGFb signals in the LRP1-deficient vascular wall. LRP1 may
function as an integrator of proliferative and anti-proliferative signals that control physiological mechanisms common to the
pathogenesis of Marfan syndrome and atherosclerosis, and this is essential for maintaining vascular wall integrity.
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in the Vascular Wall: Implications for Marfan Syndrome. PLoS ONE 2(5): e448. doi:10.1371/journal.pone.0000448
INTRODUCTION
Cholesterol-induced atherosclerosis is a major cause of morbidity
and mortality in Western societies. In the liver, the low-density
lipoprotein (LDL) receptor functions in concert with another LDL
receptor family member, the LDL receptor-related protein 1
(LRP1), in removing cholesterol carrying lipoprotein particles from
the bloodstream. However, in the smooth muscle cells of the artery
wall LRP1 acts through a different, cholesterol-independent
mechanism in the maintenance of vascular wall integrity and
atherosclerosis prevention, which relies in part on the ability of
LRP1 to regulate the activity and subcellular trafficking of the
PDGFRb [1–3]. SmLRP2 mice that lack LRP1 in vascular
smooth muscle cells show thickening of the muscular layer and
greatly increased susceptibility to atherosclerotic lesion develop-
ment, even at low plasma cholesterol levels. On a high cholesterol
diet, lesion development and progression is dramatically acceler-
ated, resulting in the occlusion of major arteries within 2 months
of cholesterol feeding. Pharmacologic inhibition of PDGFRb
signaling reduced both lesion progression and smooth muscle
over-proliferation, suggesting that the abnormal activation of
PDGFRb is at least in part responsible for the accelerated lesion
development and progression [1].
On the other hand, the characteristic disruption of elastic layers,
elongation of the aortas and aneurysms are hallmarks of Marfan
syndrome (MFS) [4,5], an autosomal dominant genetic disease.
MFS is caused by loss of function mutations in fibrillin-1,
a microfibrillar protein that coats the surface of elastic fibers
where it binds and immobilizes the TGFb large latency complex
(LLC) [6]. Haploinsufficiency of fibrillin-1 [7,8] markedly changes
the extracellular targeting, sequestration and turnover of latent
TGFb, resulting in pronounced activation of the growth factor and
the signaling pathway [4,5,9]. A phenotypically similar Marfan-
like syndrome is caused by loss of function mutations in TGFb
receptors 1 or 2 [10–12], which nevertheless result in a paradoxical
activation of the pathway and nuclear accumulation of pSmad2
[10]. Thus, abnormal activation of TGFb signaling appears to be
a common feature of Marfan and Marfan-like disorders.
Recently, LRP1 was reported to be identical to TGFbR(V),
which is coexpressed together with TGFb receptors I, II and III.
LRP1/TGFbR(V) is required for mediating the growth inhibitory
response of TGFb, in conjunction with Smad2/3 signaling
through TGFbR(I) and (II) [13,14]. TGFb1 can induce the
expression of connective tissue growth factor (CTGF), PDGF-B
and PDGF receptors [15–19]. Activation of a PDGF/PDGFR
autocrine loop by TGFb mediates epithelial-mesenchymal transi-
tion and constitutes a crucial mechanism that enhances tumor
metastasis [20] and the malignancy of gliomas [21]. All of these
proteins are not only ligands for LRP1, they also promote smooth
muscle cell proliferation [16,22]. Furthermore, TSP1, another
ligand for LRP1 and a TGFb target gene [23], directly mediates
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the conversion of latent TGFb to the active form [24,25] and
TSP1 binding to an LRP1/calreticulin complex regulates cell
adhesion [26]. Thus, LRP1 is tightly involved in the control of
growth regulating signaling processes that involve TGFb, PDGF,
and their receptors. This prompted us to investigate, whether
abnormal activation of TGFb signaling could be responsible for
the striking disruption of the elastic fiber network, fibrosis, and
accelerated atherosclerotic lesion development in the vascular wall
of smLRP2 mice [1].
RESULTS
Activation of TGFb signaling in LRP1-deficient VSMC
Vascular wall fibrosis, disruption of elastic layers, and tortuousity of
the aorta were suggestive of abnormal TGFb signaling in smLRP-
deficient mice. To obtain further evidence for the presence of
increased TGFb activity, we used immunohistochemistry to visualize
the levels of TGFb1 and TSP1, as well as the phosphorylated forms
of Smad-1 and Smad-2, the intracellular mediators of TGFb family
signals, in aortas from cholesterol-fed, LDL receptor deficient mice
expressing (LRP+) or not expressing LRP1 (LRP2) in their VSMC
(Figure 1). Expression of TSP-1, a direct TGFb1 target gene, was
strikingly increased in LRP2 compared to LPR+ aortas (Panels a and
b), whereas total TGFb1 immunoreactivity was slightly reduced
(Panels c and d), consistent with an increased activation and turnover
of matrix-associated TGFb.
TGFb1 and other TGFb family members, as well as angiotensin
II are prominent inducers of Smad2-dependent target gene
transcription, resulting in collagen deposition and disruption of the
elastic layers in the vascular wall [27,28]. Prominent accumulation of
nuclear phosphorylated Smad2/3 (pSmad2/3) was found in VSMC
in the absence of LRP1 (Panels e and f). This effect was specific for
Smad2, which is the target of TGFb signals, but not for Smad1,
which responds to signals elicited by bone morphogenic proteins
(BMPs). pSmad1 was not significantly elevated in the absence of
LRP1 (Panels g and h). These findings, taken together with the
molecular properties of LRP1, make it likely that TGFb signaling in
VSMC is indeed selectively increased in the absence of LRP1.
Rosiglitazone reduces TGFb signals in vitro and in
vivo
PPARc agonists of the thiazolidinedione class have been reported to
inhibit TGFb signaling, CTGF expression and fibrosis [29,30], and
they also can reduce atherosclerosis [31]. We therefore decided to
test, whether activation of PPARc by rosiglitazone, a compound of
this class that is in clinical use, might result in reduced nuclear
accumulation of pSmad2 and suppression of atherosclerosis in mice
lacking LRP1. We first examined the effect of rosiglitazone on
PDGFRb and pSmad2/3 levels in cultured cells in vitro. While
TGFb1 only moderately elevated PDGFRb expression in vitro, it
markedly increased pSmad2/3 levels in cultured human VSMC and
in murine fibroblasts. This increase was significantly blunted when
the cells were pretreated with rosiglitazone (Figure 2).
To test, whether rosiglitazone was able to correct the abnormal
accumulation of pSmad2/3 levels and activation of PDGFRb
signaling in smLRP deficient animals in vivo, we fed smLRP+ and
smLRP2 animals a cholesterol-rich diet that either contained or
did not contain rosiglitazone for 5 weeks (Figure 3). Aortic extracts
were prepared as described earlier [1] and analyzed by
immunoblotting (Panel A). Rosiglitazone treatment (lane 3)
significantly reduced the elevated pSmad2/3, PDGFRb and
pErk1/2 in smLRP2 aortas (lane 2) compared to smLRP+
controls (lane 1). We verified this result by immunofluorescence
staining of aortas (Panel B). Rosiglitazone treatment (Panels c, f, i)
abolished the increased nuclear pSmad2/3, overexpression of
PDGFRb, and the increased pErk1/2 levels in the smLRP2
animals (Panels b, e, h). As had been shown previously using the
tyrosine kinase inhibitor Gleevec [1], rosiglitazone treatment also
considerably improved the integrity of the elastic layers (Panel C).
Figure 1. Increased pSmad2/3 expression and activation of TGFb
signaling in LRP2 mouse aorta. Longitudinal sections of abdominal
aorta from SM22Cre+;LRPflox/flox;LDLR2/2 (LRP2) and LRPflox/flox;LDLR2/2
(LRP+) mice were stained with anti-TSP1, anti-TGFb1, anti-pSmad2/3
and anti-pSmad1 antibodies. Reduced LRP1 expression results in greatly
enhanced expression of pSmad2/3 and its target gene, TSP1. By
contrast, TGFb1 levels were slightly reduced, pSmad1 levels did not
change. Bar in a indicates 20 mm.
doi:10.1371/journal.pone.0000448.g001
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Rosiglitazone prevents atherosclerosis in smLRP2
mice
Thiazolidinediones have been reported to protect male LDLR-
deficient mice from developing atherosclerotic lesions [31],
coinciding with reductions in gelatinase and TNFa expression.
To test whether blockade of the increased Smad activation by
rosiglitazone would also reduce the marked atherosclerosis in the
smLRP2 mice, we quantitatively examined the aortas from the
atherogenic diet-fed mice. Atherosclerotic lesion areas were
significantly reduced in the presence of the PPARc agonist
(Figure 4A and C), and the striking thickening and fibrosis of the
LRP deficient vessel wall was almost completely abolished
(Figure 4B). Importantly, these changes were not caused by or
secondary to any effect of rosiglitazone on the plasma lipoprotein
profile, triglyceride or cholesterol levels (Figure 4D–F).
DISCUSSION
The findings we have presented here reveal a novel mechanism by
which the multifunctional receptor LRP1 functions as an
integrator of two distinct cellular signaling pathways in the
vascular wall. They also suggest a functional relationship between
the molecular events that underlie MFS, the formation of
aneurysms and atherosclerosis. Our results show that LRP1
controls Smad2/3-as well as PDGF-dependent signaling in VSMC
in a coordinated fashion and by distinct mechanisms.
LRP1 is a target of PDGFRb-dependent Src kinase activation
[2,32] and we showed earlier that loss of LRP1 expression in VSMCs
results in increased PDGFRb expression and activation [1,3]. In the
present study we have demonstrated, that loss of LRP1 expression
also results in increased Smad2/3-dependent signaling in VSMCs. A
potent inducer of Smad2 phosphorylation and nuclear translocation
is TGFb [33]. Moreover, induction of PDGF as well as PDGFRb
expression in response to TGFb stimulation has been recognized as
an important component of epithelial-mesenchymal transition,
a process that underlies metastasis of some tumors [20] and
increases the aggressiveness of others [21]. Our results show that
increased pSmad2/3 signaling in the LRP1-deficient vascular wall
results in increased PDGFRb expression and activation, making it
likely that TGFb is directly involved.
Figure 2. Rosiglitazone treatment decreases expression of PDGFRb and activation of Smad2/3 (pSmad2/3) in vitro. Western blot analysis of
activated Smad2/3 and PDGFRb in whole cell lysates from human VSMC and MEF LRP+/+ cells pretreated 0, 24 or 48 hours with rosiglitazone at 1025M
and then stimulated with human TGFb1 (200 pM) for 0, 1.5, 3 or 6 hours.
doi:10.1371/journal.pone.0000448.g002
Figure 3. Activation of TGFb and PDGF signaling in LRP2 mouse aortas are both prevented upon rosiglitazone treatment. Mice had been
cholesterol-fed for 5 weeks in the absence (2Rosi) or presence (+Rosi) of rosiglitazone (GlaxoSmithKline, 25 mg/kg/day) before analysis. Mouse
aortas expressing (LRP+) or not expressing (LRP2) LRP in VSMC were analyzed by western blot (Panel A) and immunohistochemistry (Panel B) for
expression of PDGFRb (d–f), and for activation of Smad2/3 (pSmad2/3, a–c), and Erk1/2 (pErk1/2, g–i). Panel C shows elastic staining of corresponding
sections and gaps in elastic fiber continuity (arrows). Bar indicates 40 mm, insert scale bar in B,a indicates 10 mm.
doi:10.1371/journal.pone.0000448.g003
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Furthermore, LRP1/TGFbR(V), can directly bind TGFb1
[13], as well as enter into a complex with TGFbR(I) [34]. By
binding and endocytosis of the active growth factor and also by
sequestering TGFbR(I) away from TGFbR(II), LRP1 is in a central
position where it can suppress the normal mode of TGFb signaling
and Smad2/3 activation through the TGFbR(I)/R(II) complex. In
addition, LRP1 mediates the endocytosis of TSP1 as well as
several matrix metalloproteinases (MMP) from the extracellular
space [35–37], and TSP1 as well as active MMP2 and MMP9
levels are increased in smLRP deficient aortas (Figure 1, and [1]).
TSP1 and MMPs potently and independently activate TGFb1
[24,25,38]. Loss of smLRP would thus be predicted to activate
TGFb/Smad signaling in VSCM by multiple independent
mechanisms, and this is consistent with the dramatically increased
nuclear pSmad2/3 levels in smLRP2 aortas (Figure 1). The
resulting disruption of elastic layers, vascular fibrosis, elongation
and distension of the aorta, and high incidence of aortic aneurysms
directly support the pivotal role of TGFb signaling in the
pathogenesis of MFS and reveal LRP1 as a critical regulator of
this pathway in vivo. As such, LRP1 could conceivably contribute
as a genetic modifier to the variable severity of expression of MFS
in humans.
We have further demonstrated the importance of TGFb
signaling through pharmacological intervention and reversal of
the smLRP2 phenotype with the PPARc agonist rosiglitazone.
Activation of PPARc with thiazolidinediones potently inhibits
TGFb signaling in vitro and in vivo [29,39,40]. The striking effect
of rosiglitazone on the nuclear accumulation of pSmad2/3 and the
near complete reversal of the aortic wall thickening and fibrosis,
and prevention of atherosclerotic lesion progression confirm the
central importance of TGFb pathway activation for this
phenotype. PPARc agonists might thus complement and enhance
the potential therapeutic use of the angiotensin II type 1 receptor
blocker Losartan in the treatment of MFS [27].
Increased susceptibility to atherosclerosis is not a part of the
MFS complex, but a striking feature of smLRP2 mice [1].
Likewise, PPARc agonists are only partially effective against diet-
induced atherosclerosis in LDLR deficient mice when LRP1 is
functional [31]. By contrast, we have shown that rosiglitazone (this
study) as well as the PDGFR tyrosine kinase inhibitor Gleevec [1]
are highly potent in protecting smLRP2 mice from atherosclerosis.
Our findings thus suggest that abnormal activation of PDGFRb
signaling, which has so far not been reported in MFS, is the major
mediator of the increased atherosclerosis in the smLRP2 mice,
and that increased PDGFRb activity is brought about by two
independent and synergistic mechanisms. First, activation of
Smad/TGFb signals in the absence of LRP1 results in the
disruption of elastic layers and a tortuous aorta [1], as well as
increased expression of PDGF receptors (Figure 2 and 3)
[15,20,41]. However, since LRP1 also controls PDGFRb activity
and recycling at the level of the plasma membrane [3], loss of
LRP1 in smooth muscle cells also results in a greatly increased
mitogenic response, VSMC proliferation and the promotion of
atherosclerotic lesion formation. This second event is prevented in
MFS by the presence of LRP1, which suppresses the abnormal
PDGFRb activation through a posttranslational mechanism [3].
Thus, rosiglitazone (as a Smad/TGFb antagonist) and Gleevec (as
a PDGFRb inhibitor) act at different steps in a linear sequence of
events (Figure 5) that result in a Marfan-like syndrome and
culminate in extensive atherosclerosis in smLRP2 artery walls.
Nevertheless, blockade of PDGFRb signaling alone by admin-
istration of Gleevec was sufficient to reduce atherosclerotic lesion
progression, as well as vascular wall thickness, in smLRP2 mice
[1], suggesting that signaling through this pathway is necessary for
elastic layer disruption and wall thickening. This raises the
possibility that PDGFRb signaling may be activated to some
extent in the Marfan vessel wall, or alternatively the mere
suppression of its baseline activity may be sufficient to normalize
the vessel wall thickening that is initiated by increased TGFb
activity. Consistent with an important role of PDGFRb in vascular
thickening is a recent report that showed transphosphorylation of
a truncated PDGFRb induced by the Angiotensin II type 1
receptor (AT1) [42], which can also activate Smad2-dependent
signals independent of TGFb [28]. AT1 is inhibited by Losartan,
Figure 4. Quantitative analysis of atherosclerotic lesion size in aortas
from cholesterol-fed mice with or without rosiglitazone treatment.
(A) Aortas from 20-week-old mice that express (LRP+) of lack (LRP2) LRP
in VSMC (n= 6 mice per group). Mice had been cholesterol-fed for
5 weeks in the absence (2Rosi) or presence (+Rosi) of rosiglitazone
(GlaxoSmithKline, 25 mg/kg/day) before analysis. Aortae were stained
en face with Sudan IV and arrows indicate lipid-laden (Sudan-positive)
atherosclerotic lesions. Scale bar, 1.2 cm. (B) Histological analysis of
thoracic aortas from animals cholesterol-fed in the absence or presence
of rosiglitazone. Hematoxylin and eosin (a and b, LRP+; c and d, LRP2),
and trichrome staining (e and f, LRP2) of longitudinal sections. Scale bar
in a, 15 mm. (C) Quantitative analysis of atherosclerotic lesion size in
aortas from cholesterol-fed LRP2 and control (LRP+) mice (n = 5 mice
per group) with and without rosiglitazone treatment. Values are
expressed as mean6s.e.m. *, p,0.05 for LRP2 treated versus untreated.
(D) FPLC profile of plasma lipoproteins from untreated LRP2 (filled
squares) and LRP+ (opened squares) and rosiglitazone treated LRP2 (filled
triangles) and LRP+ (opened triangles). (E) Plasma triglycerides and (F)
cholesterol from untreated and rosiglitazone treated LRP2 and LRP+mice.
Values are expressed as mean6S.E.M. (n=10 mice per group).
doi:10.1371/journal.pone.0000448.g004
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a drug that also reduced wall thickening in a mouse model of
Marfan syndrome [27]. Taken together, these findings indicate
a critical role for Smad2-and AT1-dependent signaling mechan-
isms in Marfan and Marfan-like syndromes and identify PDGFRb
as another important component of the pathogenic mechanism.
Our findings also suggest that rosiglitazone, a clinically approved
antidiabetic drug, may be useful for the treatment of vasculo-
pathies that are caused by increased TGFb signaling, e.g. Marfan
syndrome, as well as for the supportive treatment of certain
malignancies, such as malignant glioblastomas [43].
MATERIALS AND METHODS
Transgenic mice and diets
Homozygous LDL receptor (LDLR2/2) animals LRP deficient in
vascular smooth muscle cells (SM22-Cre+;LRPflox/flox;LDLR2/2,
referred to as smLRP2 or LRP2) have been described previously
[1] and were maintained on Teklad 6% (w/w) Mouse/Rat Diet
7002 from Harlan Teklad Premier Laboratory Diets (Madison,
WI). Six weeks prior to sacrifice, 3–6 months old LRP2 and
littermate controls (LRPflox/flox;LDLR2/2, noted LRP+) were
placed on a high-fat/high-cholesterol (Paigen) diet containing
(21% (w/w) milk fat, 1.25% (w/w) cholesterol, 0.5% (w/w) cholic
acid) and where indicated, the PPARc agonist rosiglitazone
(AdvantiaH, GlaxoSmithKline, 25mg/kg/day) was mixed into
the diet. All animals used in the experiments were age and sex
matched as closely as possible. All animal experiments were
conducted according to procedures approved by the institutional
Animal Care and Use Committee (IACUC) at UT Southwestern.
Whole Aorta staining
After 4% paraformaldehyde cardiac perfusion, the whole aortas of
animals from the different treated groups were carefully dissected
from the heart to the iliac bifurcation. The vessels were rinsed in
PBS and dissected to remove connective tissue and attached fat.
The vessels were opened longitudinally and stained for lipids with
Sudan IV. Atherosclerosis in the aortas was measured by
quantitation of Sudan IV–positive lesions as described [44].
Whole mount preparations of the vessels were photographed and
digitized. Sudan IV–positive lesions were delineated and analyzed
using NIH Image software (NIH, Bethesda, Maryland, USA).
Histology
Aortic tissue was fixed over night with 4% paraformaldehyde and
embedded in paraffin. Longitudinal and transverse sections
(10 mm thick) were stained with hematoxylin-eosin under standard
conditions.
Immunofluorescence microscopy
Anesthetized wt and LRP KO mice were perfused through the left
cardiac ventricle with warmed Hank’s balanced salt solution
(20 mM Hepes, pH 7.3) followed by the same solution containing
4% (w/v) paraformaldehyde. Aortas were removed and divided
into small pieces. The tissue was immersion-fixed for an additional
hour followed by treatment with a mixture of 60% (v/v) methanol,
10% (v/v) glacial acetic acid, 30% (v/v) inhibisol (1,1,1-
trichloroethane) for 24 hours. Tissues were then embedded in
paraffin. Paraffin sections (5 mm thick) were dewaxed in three
changes of xylene (10 minutes each) and rehydrated in PBS.
Sections were washed with 50 mM NH4Cl in PBS for 30 minutes
and blocked by incubation for 1 h in TBS (10 mM Tris-HCl,
pH 9.0, 150 mM NaCl) containing 10% (v/v) normal goat serum
and 1% (w/v) bovine serum albumin. Samples were then
incubated overnight at 4˚C with rabbit antiserum raised against
pSmad2 (1:200 dilution), PDGFRb (1:100 dilution), phospho-Erk
(1:100 dilution), or preimmune rabbit serum (1:100 dilution).
Sections were washed three times in TBS containing 0.1% bovine
serum albumin, and bound primary antibody was detected by
incubation for 2 h with Alexa-Fluor 488-conjugated goat anti-
rabbit IgG (10 mg/ml, Molecular Probes, Eugene, OR). The
tissues slides were washed three times in TBS containing 0.1%
bovine serum albumin, rinsed with water, and mounted using
Fluorescence Mounting Medium (DakoCytomation). Images were
taken using a Leica TCS SP confocal microscope.
Lipid and Lipoprotein analyses
At sacrifice, blood was collected by cardiac puncture and plasma
was analyzed by FPLC on a Superose 6 column (Sigma Chemical
Co.). Plasma and liver cholesterol content was determined
spectrofluorimetrically as described previously [45].
Western blotting
MEF LRP deficient cells were seeded in 100 mm dishes (300 000
cells/dish) and grown to confluency in 10 ml DMEM supple-
Figure 5. Control of TGFb and PDGF signaling and protection of
vascular wall integrity by LRP1. Absence of LRP1 results in increased
activation of TGFb signaling. This is accompanied by disruption of
elastic layers, tortuous aortas and increased fibrosis similar to what is
observed in Marfan and Marfan-like syndromes in which the genes for
fibrillin-1 or TGFb receptors are defective. Loss of LRP1 expression leads
to increased expression of PDGF receptors. LRP1 also controls PDGFRb
signaling and trafficking through an independent mechanism, and
absence of LRP1 promotes VSMC proliferation and severe atheroscle-
rosis. Rosiglitazone blocks TGFb signaling upstream of PDGFR, which is
inhibited by Gleevec. Both drugs are thus effective in reducing arterial
wall thickening and atherosclerosis, which are induced by increased
PDGFR signaling.
doi:10.1371/journal.pone.0000448.g005
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mented with 10% (v/v) fetal calf serum and antibiotics. MEF LRP
deficient cells were either left untreated or treated for the indicated
times with the PPARc agonist rosiglitazone under reduced serum
conditions (0.2% fetal calf serum), followed by stimulation with
recombinant human TGFb1 (200 pM) for 0, 1.5, 3 or 6 hours.
Whole cell lysates were then prepared as described previously [1],
subjected to SDS polyacrylamide gel electrophoresis, transferred
to poly(vinylidene) fluoride (PVDF) membranes (Millipore), and
blotted for phospho-Smad2/3 or PDGF receptor-b using specific
antibodies directed against PDGF receptor-b and phospho-
Smad2/3 (S465/467), respectively (all from Upstate Biotechnol-
ogy Incorporated, Lake Placid, NY). Proteins were detected using
enhanced chemiluminescence (ECL; Amersham Pharmacia Bio-
tech Inc, Piscataway, NJ).
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